Literature DB >> 11041898

Vertebral fracture risk with long-term corticosteroid therapy: prevalence and relation to age, bone density, and corticosteroid use.

V Naganathan1, G Jones, P Nash, G Nicholson, J Eisman, P N Sambrook.   

Abstract

BACKGROUND: Few data are available regarding vertebral fracture risk in patients treated with oral corticosteroids. The aim of this study was to determine the prevalence and the role of risk factors such as age, bone mineral density (BMD), and corticosteroid use for vertebral deformity in patients receiving long-term corticosteroid therapy.
METHODS: Thoracolumbar x-ray films, BMD, and details on corticosteroid use were obtained on 229 consecutive patients treated with long-term corticosteroid regimens (> or = 6 months of prednisone, > or = 5mg/d or equivalent) seen at 4 referral centers. Comparisons were made with a population control group of 286 male and female controls not taking corticosteroids (aged > or = 60 years).
RESULTS: Sixty-five patients (28%) had at least 1 vertebral deformity and 25 (11%) had 2 or more vertebral deformities. Older age, independent of BMD, was a significant risk factor for deformity. Patients aged 70 to 79 years had a 5-fold increased risk of deformity compared with patients younger than 60 years (odds ratio, 5.13; 95% confidence interval, 2.03-13.0). Compared with the population controls, the prevalence of deformities increased to a greater extent with each decade of age in the corticosteroid group (P =.005). Mean lumbar spine and femoral neck BMD Z scores were lower in the steroid-treated patients with deformities compared with the nonsteroid control group with deformities. When the effects of age, sex, body mass index, and duration of corticosteroid use were adjusted for in logistic regression analysis, low BMD was a modest predictor of deformity (for a 1-SD decrease in lumbar spine BMD: odds ratio, 1.31; 95% confidence interval, 1.02-1.68) and for a 1-SD decrease in femoral neck BMD: odds ratio, 1.77; 95% confidence interval, 1.07-2.94).
CONCLUSIONS: The combination of increasing age and corticosteroid use is associated with a marked increase in the risk of vertebral deformity. Elderly patients commencing long-term corticosteroid therapy should be considered for antiosteoporotic therapy independently of their BMD. Arch Intern Med. 2000;160:2917-2922

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11041898     DOI: 10.1001/archinte.160.19.2917

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  32 in total

1.  Low bone density and bone metabolism alterations in Duchenne muscular dystrophy: response to calcium and vitamin D treatment.

Authors:  M L Bianchi; L Morandi; E Andreucci; S Vai; J Frasunkiewicz; R Cottafava
Journal:  Osteoporos Int       Date:  2010-05-11       Impact factor: 4.507

2.  Body composition and vertebral fracture risk in female patients treated with glucocorticoid.

Authors:  H Kaji; T Tobimatsu; J Naito; M-F Iu; M Yamauchi; T Sugimoto; K Chihara
Journal:  Osteoporos Int       Date:  2005-12-31       Impact factor: 4.507

Review 3.  Minireview: live and let die: molecular effects of glucocorticoids on bone cells.

Authors:  Lorenz C Hofbauer; Martina Rauner
Journal:  Mol Endocrinol       Date:  2009-05-28

Review 4.  Bone involvement in exogenous hypercortisolism.

Authors:  L Sinigaglia; D Mazzocchi; M Varenna
Journal:  J Endocrinol Invest       Date:  2008-04       Impact factor: 4.256

5.  Urinary deoxypyridinoline is a BMD-independent marker for prevalent vertebral fractures in postmenopausal women treated with glucocorticoid.

Authors:  H Kaji; M Yamauchi; T Yamaguchi; T Sugimoto
Journal:  Osteoporos Int       Date:  2009-11-14       Impact factor: 4.507

6.  Effects of iguratimod on glucocorticoid-induced disorder of bone metabolism in vitro.

Authors:  Akira Miyama; Kosuke Ebina; Makoto Hirao; Gensuke Okamura; Yuki Etani; Kenji Takami; Atsushi Goshima; Taihei Miura; Shohei Oyama; Takashi Kanamoto; Hideki Yoshikawa; Ken Nakata
Journal:  J Bone Miner Metab       Date:  2021-02-09       Impact factor: 2.626

7.  Strategies for the prevention and treatment of osteoporosis in patients with rheumatoid arthritis.

Authors:  Kristine Phillips; Antonios Aliprantis; Jonathan Coblyn
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

Review 8.  Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data.

Authors:  J A P Da Silva; J W G Jacobs; J R Kirwan; M Boers; K G Saag; L B S Inês; E J P de Koning; F Buttgereit; M Cutolo; H Capell; R Rau; J W J Bijlsma
Journal:  Ann Rheum Dis       Date:  2005-08-17       Impact factor: 19.103

9.  Comparison of ultrasound and X-ray absorptiometry bone measurements in a case control study of female rheumatoid arthritis patients and randomly selected subjects in the population.

Authors:  G Haugeberg; R E Ørstavik; T Uhlig; J A Falch; J I Halse; T K Kvien
Journal:  Osteoporos Int       Date:  2003-04-16       Impact factor: 4.507

10.  Bone status in glucocorticoid-treated men and women.

Authors:  E S Leib; R Winzenrieth
Journal:  Osteoporos Int       Date:  2015-08-08       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.